1025482-52-3

Upstream product

• 1025482-50-1 acetic acid (6-chloro-pyridin-3-yl)-phenyl-methyl ester 
• 80100-47-6 6-chloro-α-phenyl-3-pyridinemethanol 
• 23100-12-1 6-chloronicotinylaldehyde 
• 557-21-1 zinc(II) cyanide 
• 1025482-51-2 3-(6-chloro-pyridin-3-yl)-2,2-dimethyl-3-phenyl-propionic acid methyl ester 

Downstream Products

• 1025482-53-4 methyl 3-(6-(aminomethyl)pyridin-3-yl)-2,2-dimethyl-3-phenylpropanoate 
• 1025482-35-2 C₂₆H₂₁ClFN₅OS 
• 1025482-54-5 methyl 3-(6-(formamidomethyl)pyridin-3-yl)-2,2-dimethyl-3-phenylpropanoate 
• 1025482-55-6 methyl 3-imidazo[1,5-a]pyridin-6-yl-2,2-dimethyl-3-phenylpropanoate 
• 1025482-57-8 methyl 3-(1-bromo-imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenylpropanoate 
• 1025482-64-7 3-(1-(3-cyanophenyl)-imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenylpropanoic acid 

Relevant academic research and scientific papers

Heterocyclic glucocorticoid receptor modulators with a 2,2-dimethyl-3- phenyl-N-(thiazol or thiadiazol-2-yl)propanamide core

A series of heterocyclic glucocorticoid receptor (GR) modulators with 2,2-dimethyl-3-phenyl-N-(thiazol or thiadiazol-2-yl)propanamide core are described. Structure-activity relationships suggest a combination of H-bond acceptor and a 4-fluorophenyl moiety as being important structural components contributing to the glucocorticoid receptor binding and functional activity for this series of GR modulators.

MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1 and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I): its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein the group X is O or (Rx)(Ry); is heterocyclo or heteroaryl; E is —N—, —NR1—, —O—, —C(=O), —S—, —SO2—, or —CR2—; F is —N—, —NR1a, —O—, —C(=O), —S—, —SO2—, or —CR2a—; G is independently N, —NR1b—, —O—, —C(=O), —S—, —SO2— or —CR2b— provided that the heterocyclic ring formed does not contain a S—S or S—O bond and at least one of E, F and G is a hetero atom; and Ma, Rx, Ry, R1, R1a, R1b, R2, R2a, R2b, R4, R5a, R6, R7, X, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases employing said compounds.